调节肠道菌群治疗非酒精性脂肪肝的研究进展  

Research Progress of Intestinal Microbiota Regulation in the Treatment of Nonalcoholic Fatty Liver

作　　者：刘巧红 赵瑜[1,3] 胡义扬[1,2,3] LIU Qiao Hong;ZHAO Yu;HU Yiyang(Shuguang Hospital & Institute of Hepatology,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Clinical Research Center,Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Key Laboratory of Liver and Kidney Diseases,Ministry of Education,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属曙光医院/上海中医药大学肝病研究所,上海201203 [2]上海中医药大学附属曙光医院临床研究中心,上海201203 [3]肝肾疾病病证教育部重点实验室,上海201203

出　　处：《世界中医药》2020年第7期1075-1079,共5页World Chinese Medicine

基　　金：国家自然科学基金重点项目(81830119);上海申康三年行动计划(16CR1019A)。

摘　　要：近年来的研究表明,肠道微生物群的生态失调、炎性反应和黏膜免疫功能受损是NAFLD发生发展的重要因素。调节肠道菌群是治疗非酒精性脂肪肝的重要策略和治疗靶位之一,具有良好的前景。现综述通过调节肠道菌群治疗非酒精性脂肪肝的研究进展,如益生菌、抗生素、黏附分子、肠菌移植,以及中医药在非酒精性脂肪肝中的应用研究。Recent studies have shown that ecological imbalance of intestinal microbiota,inflammation and impaired mucosal immune function are important factors for the occurrence and development of NAFLD.This paper reviews the research progress in the treatment of non-alcoholic fatty liver by regulating intestinal microbiota,such as probiotics,antibiotics,adhesion molecules,intestinal bacteria transplantation,and the application of traditional Chinese medicine in non-alcoholic fatty liver.The authors believes that the regulation of intestinal microbiota is one of the important strategies and targets for the treatment of non-alcoholic fatty liver and has a good prospect.

关 键 词：肠道菌群 非酒精性脂肪性肝病 研究进展 益生菌 抗生素 黏附分子 肠菌移植 中药 

分 类 号：R242[医药卫生—中医临床基础]